



**INTERNATIONAL JOURNAL OF
PHARMACEUTICAL SCIENCES**
[ISSN: 0975-4725; CODEN(USA): IJPS00]
Journal Homepage: <https://www.ijpsjournal.com>



Review Paper

Tumor-Type–Specific Constraints and Opportunities in Cancer Nanomedicine: A Comparative Review of Therapeutic Nanoplatfoms in Breast, Lung, Brain, and Pancreatic Cancers

Yash Srivastav¹, K. Navaneetha², Amanjot Kaur³, Sanjeeta Nayak⁴, Milan Kumar Tarei⁵, Renuka Deshpande⁶, Rishikesh Deshmukh⁷, Swatantr Bahadur Singh⁸, Pratyush Mishra*⁹

¹Assistant Professor, Department of Pharmacy, Shri Ramswaroop Memorial University (SRMU), Uttar Pradesh, India

²Associate Professor, Department of Pharmaceutics, Malla Reddy Pharmacy College, Hyderabad, Telangana, India

³Associate Professor, Department of Pharmaceutical Chemistry, KC College of Pharmacy, Nawanshahr, Punjab, India

⁴Second year Post Graduate Trainee, Department of Pharmacology, MKCG Medical College, Berhampur, Ganjam, Odisha, India

⁵Assistant Professor, Department of Pharmaceutics, SVS College of Pharmaceutical Education and Research, DBATU University, Lonere, Maharashtra, India

⁶Assistant Professor, Department of Pharmacognosy, School of Pharmaceutical Sciences, Faculty of Pharmacy IFTM University, Moradabad, Uttar Pradesh, India

⁷Assistant Professor, Department of Pharmacology & Therapeutics, Maharaja Krushna Chandra Gajapati Medical College and Hospital, Berhampur, Ganjam, Odisha, India

ARTICLE INFO

Published: 13 Feb 2026

Keywords:

Nanoparticles; Tumor
Microenvironment; Targeted
Drug Delivery

DOI:

10.5281/zenodo.18628035

ABSTRACT

Cancer remains a major global health burden, with breast, lung, brain, and pancreatic cancers contributing significantly to cancer-related morbidity and mortality. Conventional treatment approaches such as chemotherapy, radiotherapy, and immunotherapy often suffer from limitations including systemic toxicity, poor tumor selectivity, and development of drug resistance. Nanomedicine has emerged as a promising therapeutic strategy that utilizes nanoscale drug delivery systems to enhance targeting efficiency, improve pharmacokinetics, and reduce adverse effects. This

*Corresponding Author: Pratyush Mishra

Address: Assistant Professor, Department of Pharmacology & Therapeutics, Maharaja Krushna Chandra Gajapati Medical College and Hospital, Berhampur, Ganjam, Odisha, India

Email ✉: nv693.eee@gmail.com

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



review provides a comparative analysis of tumor-type-specific constraints and opportunities in cancer nanomedicine, focusing on therapeutic nanoplatforms developed for breast, lung, brain, and pancreatic cancers. Various nanocarriers including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, and hybrid nanoplatforms are evaluated for their structural properties, targeting mechanisms, and clinical applicability. The review highlights passive and active targeting strategies such as enhanced permeability and retention effect, ligand-mediated targeting, and stimuli-responsive delivery systems that improve drug accumulation and therapeutic outcomes. Tumor microenvironment heterogeneity, vascular variability, immune regulation, and physiological barriers such as the blood-brain barrier and dense stromal matrix significantly influence nanoparticle delivery efficiency across different cancer types. Breast cancer demonstrates relatively higher clinical success due to defined molecular targets, whereas lung cancer faces pulmonary clearance challenges. Brain tumors present drug delivery limitations due to the blood-brain barrier, while pancreatic cancer remains highly resistant due to stromal density and poor vascularization. The review emphasizes the importance of personalized nanomedicine strategies tailored to tumor-specific biological characteristics to improve therapeutic response and clinical translation. Advancements in multifunctional nanoplatforms and theranostic systems are expected to enhance precision oncology and overcome current therapeutic limitations

INTRODUCTION

1.1 Global Burden of Cancer and Need for Advanced Therapeutics

Cancer represents one of the most significant public health challenges worldwide, accounting for millions of new diagnoses and deaths each year. According to global cancer statistics, approximately 20 million new cancer cases and nearly 10 million cancer-related deaths were reported in recent years, with breast, lung, brain, and pancreatic cancers contributing substantially to global mortality rates (Sung et al., 2021). Breast cancer remains the most commonly diagnosed malignancy among women, while lung cancer continues to be the leading cause of cancer-related mortality globally due to late diagnosis and

aggressive disease progression (Siegel et al., 2024). Brain cancers, particularly glioblastoma, demonstrate extremely poor prognosis due to their infiltrative nature and limited therapeutic options. Pancreatic cancer is also associated with one of the lowest survival rates, primarily due to delayed detection and resistance to existing treatments (Mizrahi et al., 2020). Conventional cancer therapies, including chemotherapy, radiotherapy, and immunotherapy, have significantly improved cancer management; however, they are associated with several limitations. Chemotherapy often results in systemic toxicity due to non-specific drug distribution, leading to adverse effects such as myelosuppression, gastrointestinal toxicity, and organ damage (Chabner & Roberts, 2005). Radiotherapy, although effective in localized tumor control, can cause damage to surrounding healthy tissues and is limited in treating metastatic disease (Baskar et al., 2012). Immunotherapy has revolutionized cancer treatment by enhancing immune system activation against tumor cells; however, therapeutic response remains highly variable, and immune-related adverse effects present additional clinical challenges (Sharma & Allison, 2015). These limitations highlight the urgent need for advanced therapeutic approaches capable of improving targeting specificity, reducing systemic toxicity, and overcoming drug resistance mechanisms.

1.2 Emergence of Nanomedicine in Oncology

Nanomedicine has emerged as a transformative approach in cancer therapeutics by utilizing nanoscale materials to enhance drug delivery and therapeutic efficacy. Nanotherapeutics are defined as drug delivery systems or diagnostic agents engineered at the nanometer scale, typically ranging from 1 to 100 nanometers, designed to improve pharmacokinetics, bioavailability, and target specificity (Peer et al., 2007). Various nanoplatforms have been developed for



oncological applications, including liposomes, polymeric nanoparticles, dendrimers, metallic nanoparticles, solid lipid nanoparticles, and hybrid nanocarriers (Shi et al., 2017). Nanoparticle-based drug delivery systems offer several advantages over conventional therapeutic approaches. These include enhanced drug solubility, prolonged systemic circulation, controlled drug release, and improved tumor targeting capabilities (Blanco et al., 2015). Additionally, nanocarriers can be engineered to co-deliver multiple therapeutic agents, enabling combination therapy strategies that improve treatment outcomes and reduce the likelihood of drug resistance. Targeting mechanisms in cancer nanomedicine are broadly categorized into passive and active targeting strategies. Passive targeting relies on the enhanced permeability and retention (EPR) effect, which allows nanoparticles to accumulate preferentially in tumor tissues due to abnormal tumor vasculature and impaired lymphatic drainage (Maeda et al., 2013). In contrast, active targeting involves surface modification of nanoparticles with ligands, antibodies, or peptides that selectively bind to tumor-specific receptors, thereby improving drug localization and therapeutic efficacy (Danhier et al., 2010). These advancements have positioned nanomedicine as a promising strategy for precision oncology.

1.3 Tumor Microenvironment and Heterogeneity

The tumor microenvironment (TME) plays a crucial role in cancer progression and therapeutic response. The TME consists of tumor cells, stromal cells, immune cells, extracellular matrix components, and tumor-associated vasculature, all of which contribute to tumor growth and resistance to treatment (Quail & Joyce, 2013). Stromal components, including fibroblasts and extracellular matrix proteins, often form physical

barriers that limit drug penetration and reduce nanoparticle distribution within tumor tissues (Neesse et al., 2015). Immune cells within the TME, such as tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells, contribute to immunosuppression and facilitate tumor progression. These immune components also influence nanoparticle clearance and therapeutic efficacy by modulating inflammatory responses and nanoparticle uptake (Binnewies et al., 2018). Additionally, tumor vascular structure plays a significant role in determining nanoparticle delivery efficiency. Abnormal tumor vasculature, characterized by irregular blood vessel formation and increased permeability, facilitates nanoparticle accumulation; however, poor perfusion and high interstitial fluid pressure can restrict deep tumor penetration (Jain, 2014).

Tumor heterogeneity further complicates therapeutic outcomes by introducing variability in genetic mutations, receptor expression, and metabolic pathways among different tumor types and even within the same tumor. This heterogeneity significantly influences nanoparticle targeting efficiency and therapeutic response, necessitating personalized treatment approaches.

1.4 Rationale for Tumor-Type Comparative Analysis

Different cancer types exhibit distinct anatomical, physiological, and molecular characteristics that influence the effectiveness of nanomedicine-based therapies. Breast cancer demonstrates molecular diversity, including hormone receptor-positive, HER2-positive, and triple-negative subtypes, each requiring specialized therapeutic strategies (Waks & Winer, 2019). Lung cancer presents unique challenges due to pulmonary clearance mechanisms, mucus barriers, and complex genetic alterations associated with smoking-related



carcinogenesis (Herbst et al., 2018). Brain tumors, particularly glioblastoma, are characterized by the presence of the blood–brain barrier, which significantly restricts drug delivery to central nervous system tissues. Overcoming this barrier remains one of the major challenges in brain cancer treatment (Arvanitis et al., 2020). Pancreatic cancer is distinguished by its dense stromal microenvironment and hypovascular nature, which severely limit drug penetration and contribute to therapeutic resistance (Mizrahi et al., 2020). Given these tumor-specific characteristics, a comparative analysis of nanomedicine strategies is essential for identifying tumor-type–specific constraints and opportunities. Understanding these differences enables the rational design of targeted nanotherapeutic systems tailored to the unique biological and microenvironmental features of each cancer type. Such approaches are critical for improving clinical outcomes and advancing precision oncology.

2. Fundamental Principles of Cancer Nanomedicine

Cancer nanomedicine integrates nanotechnology with oncology to improve drug delivery, enhance therapeutic specificity, and reduce systemic toxicity. Nanoplatfoms are engineered to overcome biological barriers, optimize pharmacokinetics, and improve tumor-targeted therapeutic responses. Understanding the fundamental design principles of nanocarriers, their targeting strategies, and pharmacological behavior is essential for successful clinical translation.

2.1 Types of Nanoplatfoms Used in Oncology

Various nanoplatfoms have been developed to address limitations associated with conventional anticancer therapies. These nanocarriers differ in

structural composition, physicochemical properties, and therapeutic applications.

Liposomes

Liposomes are spherical vesicles composed of phospholipid bilayers that encapsulate hydrophilic drugs in their aqueous core and hydrophobic drugs within lipid membranes. Their structural similarity to biological membranes enhances biocompatibility and reduces immunogenicity. Liposomal formulations improve drug solubility, prolong systemic circulation, and reduce toxicity associated with conventional chemotherapy (Allen & Cullis, 2013). Clinically approved liposomal drugs, such as liposomal doxorubicin, have demonstrated improved therapeutic efficacy and reduced cardiotoxicity.

Polymeric Nanoparticles

Polymeric nanoparticles are formed from biodegradable and biocompatible polymers such as poly(lactic-co-glycolic acid) (PLGA), polyethylene glycol (PEG), and chitosan. These nanoparticles provide controlled drug release, improved stability, and enhanced drug loading capacity. Polymeric nanocarriers can also be functionalized with targeting ligands to enhance selective tumor accumulation (Danhier et al., 2012). Their tunable physicochemical properties make them highly suitable for combination drug delivery strategies.

Dendrimers

Dendrimers are highly branched, tree-like macromolecules with a well-defined architecture and multiple functional surface groups. Their uniform size distribution and high drug loading capacity allow for precise drug delivery and targeted therapy. Surface modification of dendrimers with therapeutic molecules or



targeting ligands enhances their therapeutic efficiency and tumor selectivity (Chauhan, 2018).

Metal-Based Nanoparticles

Metallic nanoparticles, including gold, silver, iron oxide, and quantum dots, possess unique optical, magnetic, and electronic properties. Gold nanoparticles, for example, are widely used in photothermal therapy due to their ability to convert light into heat, leading to tumor cell destruction. Iron oxide nanoparticles are frequently employed in imaging and targeted drug delivery due to their magnetic properties (Dreaden et al., 2012).

Solid Lipid Nanoparticles

Solid lipid nanoparticles (SLNs) consist of solid lipid matrices stabilized by surfactants. They

provide improved drug stability, controlled drug release, and enhanced bioavailability. SLNs are particularly advantageous for delivering lipophilic anticancer drugs and improving therapeutic index while minimizing systemic toxicity (Mehnert & Mäder, 2012).

Hybrid and Multifunctional Nanoparticles

Hybrid nanoparticles combine multiple nanomaterials to enhance therapeutic efficacy and multifunctionality. These nanoplateforms may incorporate diagnostic imaging agents, therapeutic drugs, and targeting ligands within a single system, enabling theranostic applications. Multifunctional nanoparticles improve treatment monitoring and personalized therapeutic approaches (Mura et al., 2013).

Table 1. Major Nanoplateforms Used in Cancer Therapy and Their Characteristics

| Nanoplateform Type | Structural Composition | Key Advantages | Therapeutic Applications | Limitations |
|---------------------------|--|---|---|---|
| Liposomes | Phospholipid bilayer vesicles | High biocompatibility, improved drug solubility, reduced toxicity | Chemotherapy drug delivery, gene delivery | Limited drug loading for hydrophobic drugs |
| Polymeric Nanoparticles | Biodegradable polymers (PLGA, PEG, chitosan) | Controlled release, tunable properties, enhanced targeting | Combination therapy, gene therapy | Polymer degradation variability |
| Dendrimers | Branched polymeric macromolecules | High drug loading capacity, precise targeting | Gene therapy, targeted drug delivery | Potential cytotoxicity at high concentrations |
| Metal-Based Nanoparticles | Gold, silver, iron oxide, quantum dots | Imaging capability, photothermal therapy | Cancer imaging, photodynamic therapy | Potential metal toxicity |
| Solid Lipid Nanoparticles | Solid lipid core with surfactant stabilization | Improved stability, sustained drug release | Lipophilic drug delivery | Limited drug incorporation capacity |
| Hybrid Nanoparticles | Combination of polymeric, lipid, and inorganic materials | Multifunctionality, theranostics | Personalized cancer therapy | Complex synthesis and scalability challenges |

2.2 Targeting Strategies in Nanomedicine

Effective targeting of tumor tissues remains a critical objective in cancer nanomedicine. Targeting strategies are categorized into passive targeting, active targeting, and stimuli-responsive delivery systems.

Passive Targeting via Enhanced Permeability and Retention (EPR) Effect

Passive targeting is based on the EPR effect, which allows nanoparticles to accumulate preferentially within tumor tissues due to abnormal tumor vasculature and impaired lymphatic drainage. Tumor blood vessels are characterized by irregular endothelial gaps that permit nanoparticle extravasation. Additionally, poor lymphatic drainage in tumor tissues promotes nanoparticle retention, thereby enhancing localized drug concentration (Fang et al., 2011). However, variability in EPR efficiency among tumor types and patients remains a significant challenge.

Active Targeting Using Ligands, Antibodies, and Peptides

Active targeting involves functionalization of nanoparticle surfaces with specific ligands that bind to overexpressed receptors on tumor cells. Common targeting ligands include folic acid, transferrin, monoclonal antibodies, and tumor-specific peptides. This targeting strategy enhances cellular uptake through receptor-mediated endocytosis and improves therapeutic selectivity (Bazak et al., 2015). Antibody-conjugated nanoparticles have shown particular promise in targeting HER2-positive breast cancer and EGFR-mutated lung cancer.

Stimuli-Responsive Nanocarriers

Stimuli-responsive nanoparticles release therapeutic agents in response to internal or external stimuli such as pH changes, temperature variations, enzymatic activity, or light exposure. Tumor tissues often exhibit acidic microenvironments and elevated enzyme activity, enabling selective drug release at tumor sites. External stimuli such as ultrasound or magnetic fields further enhance drug delivery precision (Torchilin, 2014).

Table 2. Targeting Strategies in Cancer Nanomedicine

| Targeting Strategy | Mechanism | Advantages | Challenges | Examples |
|------------------------------|--|---|--|---|
| Passive Targeting | Exploits EPR effect for nanoparticle accumulation | Simple design, improved tumor localization | Tumor heterogeneity, inconsistent EPR effect | Liposomal chemotherapeutics |
| Active Targeting | Ligand-receptor interaction enables selective uptake | Enhanced specificity, improved cellular internalization | Ligand stability and immune recognition | Antibody-conjugated nanoparticles |
| Stimuli-Responsive Targeting | Drug release triggered by tumor-specific stimuli | Controlled drug release, improved safety | Complex nanoparticle design | pH-sensitive and enzyme-responsive nanocarriers |

2.3 Pharmacokinetics and Biodistribution

Pharmacokinetics and biodistribution significantly influence the therapeutic performance and safety of nanoparticle-based drug delivery systems.



Nanoparticle design parameters such as size, surface charge, and hydrophobicity play crucial roles in determining drug loading efficiency, circulation time, and tissue distribution.

Drug Loading and Release Kinetics

Nanocarriers enable encapsulation or conjugation of therapeutic agents, thereby protecting drugs from premature degradation and improving bioavailability. Controlled drug release is achieved through diffusion, degradation of carrier materials, or stimuli-triggered release mechanisms. Sustained drug release enhances therapeutic efficacy while minimizing systemic toxicity (Kamaly et al., 2016).

Circulation Time and Clearance Mechanisms

Nanoparticles with optimal size (typically 10–200 nm) exhibit prolonged circulation time and

improved tumor accumulation. Surface modification with polyethylene glycol reduces recognition by the mononuclear phagocyte system, thereby enhancing systemic stability and reducing immune clearance (Owens & Peppas, 2006). Clearance pathways for nanoparticles include renal excretion, hepatic metabolism, and uptake by immune cells.

Toxicological Considerations

Although nanomedicine offers improved therapeutic outcomes, potential toxicity remains a major concern. Nanoparticles may induce oxidative stress, inflammation, and organ accumulation, leading to long-term safety risks. Careful optimization of nanoparticle composition, size, and biodegradability is essential to minimize adverse effects and improve clinical safety (Fadeel et al., 2018).

Table 3. Pharmacokinetic Factors Influencing Nanoparticle Therapeutics

| Pharmacokinetic Parameter | Influencing Factors | Impact on Therapeutic Outcome |
|---------------------------|--|--|
| Drug Loading Efficiency | Carrier composition, drug solubility | Determines therapeutic dose and efficacy |
| Release Kinetics | Polymer degradation, environmental stimuli | Controls drug availability at tumor site |
| Circulation Time | Particle size, surface modification | Enhances tumor accumulation |
| Biodistribution | Surface charge, targeting ligands | Determines tissue selectivity |
| Clearance Mechanisms | Renal filtration, hepatic uptake | Influences toxicity and elimination |

3. Tumor-Type-Specific Nanomedicine Strategies

Tumor heterogeneity significantly influences nanomedicine performance across different cancer types. Variations in molecular profiles, tumor microenvironment, vascular architecture, and immune responses determine nanoparticle penetration, retention, and therapeutic outcomes. This section comparatively examines tumor-

specific constraints and opportunities in breast, lung, brain, and pancreatic cancers.

3.1 Breast Cancer

3.1.1 Pathophysiological Characteristics

Hormone Receptor Status and Molecular Subtypes

Breast cancer is a highly heterogeneous disease classified into molecular subtypes based on



receptor expression, including estrogen receptor-positive (ER+), progesterone receptor-positive (PR+), human epidermal growth factor receptor 2-positive (HER2+), and triple-negative breast cancer (TNBC). These subtypes differ significantly in prognosis, therapeutic response, and nanoparticle targeting potential (Perou et al., 2000). HER2-overexpressing tumors exhibit aggressive growth but offer well-defined molecular targets for antibody-conjugated nanocarriers. TNBC lacks hormone and HER2 receptors, limiting targeted therapy options and necessitating alternative nanotherapeutic strategies (Bianchini et al., 2016).

Tumor Vascularization and Immune Environment

Breast tumors typically demonstrate enhanced angiogenesis, resulting in abnormal vascular structures that promote nanoparticle accumulation through vascular leakage. However, immune cell infiltration varies among subtypes. TNBC often displays higher immune cell activity, creating opportunities for nanoparticle-mediated immunotherapy delivery (Schmid et al., 2018).

3.1.2 Major Constraints in Nanotherapeutic Delivery

Heterogeneous Receptor Expression

Receptor variability within tumor populations reduces active targeting efficiency. Even within HER2-positive tumors, receptor expression levels differ, affecting nanoparticle binding and therapeutic efficacy.

Drug Resistance Mechanisms

Breast cancer frequently develops resistance through efflux transporter overexpression, altered apoptosis signaling, and tumor microenvironment remodeling. These mechanisms reduce

intracellular drug retention and therapeutic effectiveness (Holohan et al., 2013).

Variable EPR Effect

Although breast tumors often exhibit enhanced vascular permeability, EPR effectiveness varies across tumor stages and individual patients, limiting uniform nanoparticle accumulation.

3.1.3 Nanoplatfoms and Therapeutic Opportunities

HER2-Targeted Nanoparticles

Antibody-functionalized nanoparticles targeting HER2 receptors improve therapeutic specificity and reduce systemic toxicity. Nanoparticles conjugated with trastuzumab have demonstrated improved tumor uptake and treatment efficacy.

Liposomal Drug Formulations

Liposomal doxorubicin enhances drug bioavailability while reducing cardiotoxicity, significantly improving treatment safety.

Polymer-Based Nanocarriers for Hormone Therapy

Polymeric nanoparticles facilitate sustained release of endocrine therapy agents such as tamoxifen, improving therapeutic compliance and effectiveness.

Nanotechnology in Triple-Negative Breast Cancer

Nanocarriers delivering chemotherapeutics, gene therapy, and immunomodulatory agents provide promising treatment alternatives for TNBC due to lack of conventional molecular targets (Yao et al., 2020).

3.1.4 Current Clinical Progress and Trials



Several nanoparticle-based formulations, including liposomal anthracyclines and antibody-drug conjugates, have entered clinical use. Emerging trials are investigating multifunctional nanocarriers combining chemotherapy and immunotherapy for improved TNBC treatment.

3.2 Lung Cancer

3.2.1 Tumor Biology and Disease Complexity

Non-Small Cell Lung Cancer vs Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases and is characterized by diverse genetic mutations such as EGFR, ALK, and KRAS alterations. Small cell lung cancer (SCLC) is more aggressive and rapidly metastasizing, presenting significant therapeutic challenges (Govindan et al., 2012).

Role of Smoking-Related Molecular Alterations

Smoking-induced carcinogenesis results in extensive genomic instability and tumor heterogeneity, complicating targeted nanoparticle therapy.

3.2.2 Delivery Barriers

Pulmonary Mucus Barrier

Respiratory mucus limits nanoparticle penetration and reduces effective drug delivery to lung tumors.

High Clearance by Alveolar Macrophages

Nanoparticles delivered via inhalation may be rapidly eliminated by immune cells in lung tissues.

Limited Nanoparticle Retention

Rapid clearance and mucociliary transport reduce therapeutic residence time within lung tumors.

3.2.3 Nanoparticle-Based Therapeutic Strategies

Inhalable Nanoparticle Systems

Aerosolized nanoparticles provide localized drug delivery directly to lung tissues, improving therapeutic concentration and minimizing systemic toxicity (Patton & Byron, 2007).

Targeted Nanocarriers for EGFR-Mutated Tumors

Ligand-conjugated nanoparticles targeting EGFR receptors improve selective drug uptake in NSCLC.

Nanomedicine for Immunotherapy Enhancement

Nanocarriers enhance delivery of immune checkpoint inhibitors and tumor vaccines, improving immune activation against lung tumors (Zhang et al., 2019).

3.2.4 Translational and Clinical Developments

Clinical investigations of inhalable nanoparticle formulations and nanoparticle-mediated immunotherapy demonstrate promising therapeutic outcomes, though large-scale clinical validation remains limited.

3.3 Brain Cancer

3.3.1 Glioblastoma and Other Malignant Brain Tumors

Molecular and Cellular Characteristics

Glioblastoma exhibits rapid cell proliferation, angiogenesis, and genetic heterogeneity, contributing to poor therapeutic outcomes (Ostrom et al., 2019).



Highly Aggressive and Infiltrative Nature

Brain tumors infiltrate surrounding healthy tissues, making complete surgical removal and drug targeting extremely difficult.

3.3.2 Blood–Brain Barrier as a Major Constraint

Tight Junctions Limiting Drug Penetration

BBB endothelial cells form tight junctions that restrict nanoparticle entry into central nervous system tissues.

Efflux Transporter Activity

Efflux proteins such as P-glycoprotein actively remove therapeutic agents from brain tissues.

Tumor Heterogeneity within CNS

Variation in BBB integrity across tumor regions creates uneven nanoparticle distribution.

3.3.3 Nanotechnology-Based Solutions

BBB-Crossing Nanoparticles

Surface-modified nanoparticles enable receptor-mediated transcytosis across BBB structures (Saraiva et al., 2016).

Ligand-Mediated Targeting Systems

Nanoparticles conjugated with transferrin or insulin receptors enhance brain tumor targeting.

Magnetic and Ultrasound-Assisted Delivery

Magnetic nanoparticles and focused ultrasound techniques facilitate BBB disruption and improve nanoparticle penetration.

Theranostic Nanoparticles

Theranostic nanocarriers combine imaging and therapeutic capabilities, allowing real-time treatment monitoring.

3.3.4 Clinical Advancements and Limitations

Although several BBB-penetrating nanoparticles demonstrate preclinical success, clinical translation remains limited due to safety concerns and complexity of CNS drug delivery.

3.4 Pancreatic Cancer

3.4.1 Biological and Microenvironmental Features

Dense Stromal Matrix

Pancreatic tumors contain abundant extracellular matrix proteins and fibroblasts that act as physical barriers to nanoparticle penetration (Erkan et al., 2012).

Hypovascular Nature

Limited vascularization reduces nanoparticle accumulation and drug delivery efficiency.

Immunosuppressive Microenvironment

High infiltration of regulatory immune cells suppresses immune responses and promotes tumor growth.

3.4.2 Nanotherapeutic Delivery Challenges

Poor Vascular Perfusion

Reduced blood flow limits nanoparticle transport into tumor tissues.

High Interstitial Fluid Pressure

Elevated tumor pressure prevents nanoparticle penetration and retention.

Drug Resistance



Pancreatic tumors demonstrate strong resistance mechanisms, including metabolic adaptation and stromal protection.

3.4.3 Emerging Nanoplatforms

Stromal-Degrading Nanoparticle Systems

Nanocarriers delivering enzymes or stromal-targeting drugs enhance drug penetration.

Albumin-Bound Nanoparticles

Albumin-bound paclitaxel improves drug solubility and tumor accumulation, demonstrating clinical success.

Combination Nanotherapy Strategies

Nanoparticles co-delivering chemotherapeutics and immunomodulatory agents enhance therapeutic outcomes.

Nanoparticle-Based Gene and Immunotherapy

Gene silencing and immune activation nanoplatforms show potential for overcoming resistance mechanisms (Lee et al., 2021).

3.4.4 Clinical Translation Status

Several nanoparticle-based therapies, including albumin-bound paclitaxel formulations, have received regulatory approval, while next-generation gene delivery nanoparticles are under clinical investigation.

Table 4. Comparative Tumor-Specific Nanomedicine Constraints and Opportunities

| Cancer Type | Major Biological Barriers | Nanotechnology Opportunities | Clinical Status |
|-------------------|---|--|------------------------------------|
| Breast Cancer | Receptor heterogeneity, drug resistance | HER2-targeted nanoparticles, liposomal drugs | Multiple approved nanoformulations |
| Lung Cancer | Mucus barrier, macrophage clearance | Inhalable nanoparticles, immunotherapy nanocarriers | Emerging clinical trials |
| Brain Cancer | Blood–brain barrier, tumor infiltration | BBB-crossing nanoparticles, magnetic delivery | Mostly preclinical/early clinical |
| Pancreatic Cancer | Dense stroma, hypovascular tumor | Stromal-targeting nanoparticles, albumin-based drugs | Limited but expanding approvals |



Figure 1: Tumor-Type–Specific Nanomedicine Strategy Selection

4. Comparative Analysis of Tumor-Type Nanomedicine Challenges

Nanomedicine effectiveness is strongly influenced by tumor-specific biological

characteristics and microenvironmental barriers. Breast, lung, brain, and pancreatic cancers exhibit significant differences in vascular structure, stromal architecture, immune regulation, and tissue permeability, all of which affect nanoparticle transport, retention, and therapeutic efficacy. Comparative evaluation of these factors is essential for optimizing tumor-type-specific nanotherapeutic design and improving clinical translation.

4.1 Comparative Tumor Microenvironment Barriers

The tumor microenvironment (TME) is a dynamic system consisting of tumor cells, stromal cells, immune populations, extracellular matrix components, and vascular networks. Variability in these components creates unique delivery barriers for nanoparticle-based therapies.

Vascular Density

Tumor vascularization plays a central role in nanoparticle delivery. Breast tumors often demonstrate relatively high vascular density, allowing improved nanoparticle extravasation and accumulation. In contrast, pancreatic tumors exhibit poor vascularization and reduced perfusion, significantly limiting nanoparticle transport into tumor tissues (Olive et al., 2009). Brain tumors present a complex vascular structure characterized by partially disrupted blood–brain barrier regions, resulting in heterogeneous nanoparticle distribution (Sarkaria et al., 2018). Lung tumors display variable vascular density influenced by tumor subtype and disease stage.

Stromal Composition

Stromal elements form physical barriers that influence nanoparticle diffusion and retention. Pancreatic tumors possess one of the most extensive stromal matrices among solid tumors,

composed primarily of fibroblasts and extracellular matrix proteins that hinder nanoparticle penetration (Özdemir et al., 2014). Breast tumors contain moderate stromal density, while lung tumors exhibit variable stromal composition depending on tumor subtype. Brain tumors typically have limited stromal barriers but are protected by physiological barriers such as the blood–brain barrier.

Immune Response Variability

Immune cell infiltration and inflammatory signaling influence nanoparticle uptake and therapeutic outcomes. Breast and lung tumors often demonstrate significant immune heterogeneity, affecting nanoparticle clearance and immunotherapeutic response. Pancreatic tumors display highly immunosuppressive environments dominated by regulatory immune cells that reduce treatment efficacy. Brain tumors are characterized by immune privilege and reduced lymphatic activity, limiting immune-mediated nanoparticle clearance (Jackson et al., 2019).

4.2 Differences in Nanoparticle Penetration and Retention

Nanoparticle penetration into tumor tissues is influenced by multiple physical and biological factors, including interstitial fluid pressure, extracellular matrix density, and vascular permeability.

Interstitial Pressure Differences

High interstitial fluid pressure (IFP) within tumors limits nanoparticle diffusion and drug distribution. Pancreatic tumors exhibit significantly elevated IFP due to dense stromal architecture, restricting nanoparticle penetration. Breast tumors demonstrate moderate IFP, allowing improved nanoparticle distribution compared to pancreatic



tumors. Brain tumors present regional variations in IFP, resulting in uneven drug delivery. Lung tumors often exhibit lower IFP but face alternative barriers such as mucociliary clearance (Heldin et al., 2004).

Tissue Permeability Variations

Tumor tissue permeability directly influences nanoparticle accumulation and retention. Breast tumors generally demonstrate enhanced permeability, facilitating nanoparticle uptake. Lung tumors exhibit permeability variability due to airway structures and mucus barriers. Brain tumors demonstrate restricted permeability due to intact BBB regions, while pancreatic tumors demonstrate reduced permeability due to stromal compression and limited vascular permeability (Netti et al., 2000).

4.3 Comparative Therapeutic Effectiveness

Response Variability Among Tumor Types

Nanomedicine demonstrates variable therapeutic success across tumor types. Breast cancer shows the highest clinical success rate due to well-defined molecular targets and favorable vascular

characteristics. Lung cancer demonstrates moderate therapeutic response due to respiratory barriers and tumor heterogeneity. Brain cancer presents significant challenges due to BBB restrictions and tumor infiltration patterns. Pancreatic cancer exhibits the lowest therapeutic response due to stromal barriers, hypovascularity, and strong drug resistance mechanisms (Stylianopoulos & Jain, 2013).

Personalized Nanomedicine Approaches

Personalized nanomedicine focuses on designing nanocarriers tailored to tumor-specific biological characteristics, including receptor expression, stromal density, and immune status. Advances in molecular profiling, imaging technologies, and biomarker identification enable patient-specific nanoparticle selection and treatment optimization. Personalized nanomedicine improves therapeutic outcomes by addressing tumor heterogeneity and minimizing treatment resistance (Wang et al., 2021).

Table 5. Comparative Tumor Characteristics, Delivery Barriers, and Nanoplatform Suitability

| Tumor Type | Vascular Density | Stromal Composition | Immune Environment | Penetration Efficiency | Retention Efficiency | Suitable Nanoplatforms |
|---------------|----------------------|---------------------|-------------------------------------|------------------------|----------------------|--|
| Breast Cancer | High | Moderate | Highly variable immune infiltration | High | Moderate to High | HER2-targeted nanoparticles, liposomes, polymeric nanocarriers |
| Lung Cancer | Moderate to Variable | Variable | Strong inflammatory immune activity | Moderate | Moderate | Inhalable nanoparticles, ligand-targeted nanocarriers, immunotherapy nanoplatforms |



| | | | | | | |
|-------------------|-------------------------|------------------------|-------------------------------|-----------------|----------|--|
| Brain Cancer | Variable BBB disruption | Low stromal density | Immune-privileged environment | Low to Moderate | Moderate | BBB-crossing nanoparticles, theranostic nanocarriers, magnetic delivery systems |
| Pancreatic Cancer | Low | Extremely dense stroma | Strongly immunosuppressive | Very Low | Low | Stromal-degrading nanoparticles, albumin-bound nanocarriers, gene delivery nanoparticles |

Table 6. Comparative Nanoparticle Penetration and Therapeutic Outcomes

| Parameter | Breast Cancer | Lung Cancer | Brain Cancer | Pancreatic Cancer |
|-----------------------------|--------------------------|--------------------------------|------------------------------------|------------------------------------|
| Interstitial Fluid Pressure | Moderate | Low to Moderate | Regionally Variable | Very High |
| Tissue Permeability | High | Moderate | Restricted by BBB | Low |
| Nanoparticle Distribution | Uniform in many subtypes | Variable due to mucus barriers | Highly heterogeneous | Limited due to stromal compression |
| Therapeutic Response Rate | High clinical success | Moderate response | Limited success | Low response |
| Personalization Potential | High | Moderate | High with BBB-targeting strategies | Moderate but emerging |




Figure 2: Comparative Nanomedicine Decision Framework

5. Safety, Toxicity, and Regulatory Considerations

5.1 Nanoparticle Biocompatibility

Biocompatibility is a fundamental requirement for successful clinical translation of nanomedicines. Nanoparticles (NPs) must demonstrate minimal toxicity, acceptable pharmacological behavior, and compatibility with biological systems while maintaining therapeutic effectiveness. Biocompatibility depends on physicochemical properties including particle size, shape, surface charge, composition, and surface functionalization (Suk et al., 2016). Surface engineering strategies such as polyethylene glycol (PEG) coating are widely employed to enhance nanoparticle stability, prevent aggregation, and reduce immune recognition. PEGylation also prolongs systemic circulation by reducing opsonization and reticuloendothelial system

(RES) clearance. However, PEG can induce accelerated blood clearance upon repeated dosing due to anti-PEG antibody formation (Knop et al., 2010). Lipid-based nanoparticles such as liposomes and solid lipid nanoparticles exhibit superior biocompatibility compared to metallic nanoparticles because they mimic biological membranes. Polymeric nanoparticles composed of biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA) demonstrate predictable degradation and reduced cytotoxicity, making them suitable for sustained drug delivery (Danhier et al., 2012). Metal-based nanoparticles such as gold, silver, and iron oxide nanoparticles offer unique imaging and therapeutic functionalities but may exhibit toxicity depending on particle size, surface modification, and dose exposure. Iron oxide nanoparticles are generally considered safer due to their biodegradability through natural iron metabolic pathways (Huang et al., 2017).

Table 7. Biocompatibility Characteristics of Major Nanoplatfoms

| Nanoplatfom Type | Composition | Biocompati bility Level | Advantages | Potential Concerns | Clinical Relevance |
|---------------------------|-----------------------------|-------------------------|---|--------------------------------|----------------------------------|
| Liposomes | Phospholipid bilayers | Very High | Biomimetic structure, low toxicity, approved formulations | Leakage of encapsulated drug | Widely used in oncology |
| Polymeric nanoparticles | PLGA, PEG, chitosan | High | Controlled drug release, biodegradable | Polymer degradation byproducts | Increasing clinical applications |
| Solid lipid nanoparticles | Lipid matrices | High | Enhanced stability, low cytotoxicity | Limited drug loading capacity | Emerging therapeutic use |
| Dendrimers | Branched synthetic polymers | Moderate to High | Precise drug conjugation | Cationic surface toxicity | Experimental stage |
| Gold nanoparticles | Metallic gold core | Moderate | Imaging and photothermal therapy | Long-term accumulation risk | Preclinical and translational |
| Iron oxide nanoparticles | Magnetic metal oxide | High | MRI contrast and targeted delivery | Oxidative stress at high doses | Clinical imaging and therapy |

5.2 Long-Term Toxicity and Immunogenicity

Long-term toxicity remains a critical challenge in cancer nanomedicine. Nanoparticles may



accumulate in vital organs including liver, spleen, and lungs due to RES uptake. Chronic accumulation can induce oxidative stress, inflammation, and organ dysfunction (Fadeel & Garcia-Bennett, 2010). Metal nanoparticles are particularly associated with long-term toxicity due to limited biodegradability. Gold nanoparticles, although chemically inert, may accumulate in tissues and produce delayed inflammatory responses. Conversely, biodegradable polymeric and lipid nanoparticles are metabolized into nontoxic byproducts and are generally considered safer for chronic administration (Baetke et al., 2015). Immunogenicity is another major concern. Nanoparticles may activate innate immune

responses via complement activation or cytokine release. Complement activation-related pseudoallergy (CARPA) has been reported with liposomal formulations such as liposomal doxorubicin. Surface modifications and careful dose optimization are essential to mitigate immunological reactions (Szebeni, 2014).

The protein corona formation on nanoparticle surfaces after exposure to biological fluids significantly influences biodistribution, cellular uptake, and immune recognition. Protein corona composition varies across tumor types and physiological conditions, contributing to variability in therapeutic outcomes (Monopoli et al., 2012).

Table 8. Long-Term Toxicity and Immunogenicity Profiles of Nanomedicines

| Toxicological Factor | Mechanism | Associated Nanoparticles | Clinical Implications | Mitigation Strategies |
|--------------------------|---|--|---------------------------------------|---|
| Organ accumulation | RES uptake and poor clearance | Metal nanoparticles, dendrimers | Liver and spleen toxicity | Biodegradable materials and size optimization |
| Oxidative stress | Reactive oxygen species generation | Silver and metal oxide nanoparticles | Cellular damage and inflammation | Antioxidant surface coatings |
| Complement activation | Immune system recognition | Liposomes and polymeric nanoparticles | Hypersensitivity reactions | Surface PEGylation and dose adjustment |
| Cytokine release | Immune cell activation | Cationic dendrimers and polymeric carriers | Systemic inflammatory response | Surface charge neutralization |
| Protein corona formation | Protein adsorption altering nanoparticle identity | All nanoparticle types | Altered biodistribution and targeting | Surface functionalization and biomimetic coatings |

5.3 Manufacturing and Scalability Challenges

Large-scale production of nanomedicines remains a significant barrier to clinical translation. Manufacturing challenges include reproducibility, batch-to-batch consistency, sterility, and cost-effectiveness. Minor variations in nanoparticle size or surface characteristics can significantly influence therapeutic efficacy and safety (Ventola, 2017). Scaling up laboratory synthesis to industrial production requires robust and standardized

manufacturing techniques such as microfluidic synthesis, high-pressure homogenization, and controlled precipitation methods. Microfluidic technology enables precise control over nanoparticle size and composition while improving reproducibility and scalability (Valencia et al., 2012). Quality control and characterization are essential components of nanomedicine manufacturing. Regulatory agencies require comprehensive evaluation of

particle size distribution, zeta potential, drug encapsulation efficiency, release kinetics, and stability profiles. Advanced analytical techniques including dynamic light scattering, transmission electron microscopy, and mass spectrometry are routinely used for characterization.

Cost considerations also impact commercialization. Complex multi-component

nanoparticles may involve expensive raw materials and sophisticated manufacturing processes, limiting widespread clinical adoption. Simplified nanopatform designs and modular manufacturing approaches are being explored to improve economic feasibility.

Table 9. Key Manufacturing Challenges in Cancer Nanomedicine

| Challenge | Description | Impact on Clinical Translation | Potential Solutions |
|----------------------------|--|--------------------------------------|--|
| Batch variability | Differences in particle size and drug loading | Inconsistent therapeutic outcomes | Automated and standardized synthesis |
| Sterility maintenance | Risk of microbial contamination | Reduced safety and product stability | Aseptic manufacturing processes |
| Scale-up limitations | Laboratory techniques difficult to industrialize | Delayed commercialization | Microfluidic and continuous flow synthesis |
| Quality control complexity | Multiple physicochemical parameters | Increased regulatory burden | Advanced analytical characterization |
| High production cost | Expensive materials and processing | Limited accessibility | Modular and cost-efficient nanoparticle design |

5.4 Regulatory Approval Pathways

Regulatory approval of cancer nanomedicines requires comprehensive evaluation of safety, efficacy, pharmacokinetics, and manufacturing quality. Regulatory frameworks established by agencies such as the United States Food and Drug Administration (FDA), European Medicines Agency (EMA), and Central Drugs Standard Control Organization (CDSCO) in India govern the clinical translation of nanotherapeutics.

Nanomedicines are typically regulated under conventional pharmaceutical guidelines; however, their unique physicochemical properties necessitate additional characterization and safety assessment. Regulatory agencies emphasize a

risk-based approach focusing on nanoparticle composition, degradation behavior, and biodistribution (Tinkle et al., 2014). Clinical approval pathways include preclinical toxicology studies, Phase I safety trials, Phase II efficacy trials, and Phase III large-scale clinical evaluation. Several nanomedicines such as liposomal doxorubicin and albumin-bound paclitaxel have successfully obtained regulatory approval, demonstrating feasibility of nanoparticle-based therapeutics. Post-marketing surveillance is crucial to monitor long-term safety and rare adverse events associated with nanomedicine use. Regulatory harmonization and standardized evaluation protocols are essential for accelerating global nanomedicine development and approval.

Table 10. Regulatory Requirements for Nanomedicine Approval

| Regulatory Stage | Key Requirements | Evaluation Parameters | Challenges |
|-----------------------------|-------------------------------|---|---|
| Preclinical studies | Toxicity and pharmacokinetics | Biodistribution, metabolism, organ toxicity | Complex nanoparticle behavior |
| Phase I clinical trials | Safety assessment | Dose tolerance, immune response | Limited human data |
| Phase II clinical trials | Preliminary efficacy | Tumor response and therapeutic index | Patient variability |
| Phase III clinical trials | Large-scale validation | Comparative effectiveness and safety | High cost and extended timelines |
| Post-marketing surveillance | Long-term safety monitoring | Rare adverse effects and real-world performance | Data collection and regulatory compliance |

6. Clinical Translation and Commercialized Nanomedicines

6.1 Approved Nanoformulations for Cancer Therapy

Nanomedicine has progressed from experimental research to clinical oncology practice, with several nanoparticle-based drug delivery systems gaining regulatory approval. These nanoformulations improve therapeutic index, drug solubility, pharmacokinetics, and tumor-targeting efficiency while reducing systemic toxicity. Most approved nanomedicines utilize liposomes, polymeric nanoparticles, albumin-bound nanoparticles, or lipid-based carriers (Hare et al., 2017; Shi et al., 2017). Liposome-based formulations represent one of the earliest and most successful cancer nanomedicine platforms. Pegylated liposomal doxorubicin (PLD), marketed as Doxil®/Caelyx®, was among the first FDA-approved nanotherapeutics. The PEG coating prolongs systemic circulation and enhances tumor accumulation through the enhanced permeability and retention (EPR) effect, improving treatment

outcomes in ovarian cancer, breast cancer, and Kaposi's sarcoma (Barenholz, 2012). Similarly, liposomal daunorubicin and cytarabine combinations have demonstrated significant clinical utility in hematologic malignancies.

Albumin-bound nanoparticles have also gained widespread acceptance. Nab-paclitaxel (Abraxane®) employs albumin as a natural carrier to facilitate receptor-mediated transcytosis across endothelial cells, improving intratumoral drug delivery. This formulation has been approved for breast cancer, pancreatic cancer, and non-small cell lung cancer, demonstrating superior therapeutic efficacy compared with conventional paclitaxel formulations (Desai et al., 2018).

Polymeric nanoparticles, micellar systems, and lipid nanoparticles have further expanded the clinical nanomedicine landscape. These platforms enhance drug stability, enable controlled drug release, and allow multifunctional surface modification. Lipid nanoparticle-based nucleic acid delivery systems are emerging as promising tools for gene therapy and cancer immunotherapy (Kulkarni et al., 2018).

Table 11. Selected FDA/EMA-Approved Nanomedicines for Cancer Therapy

| Nanoformulation | Drug | Nanocarrier Type | Cancer Indications | Regulatory Status |
|------------------|---------------------------|----------------------------|--|-------------------|
| Doxil® / Caelyx® | Doxorubicin | PEGylated liposome | Breast, ovarian cancer, Kaposi's sarcoma | FDA, EMA |
| Abraxane® | Paclitaxel | Albumin-bound nanoparticle | Breast, lung, pancreatic cancer | FDA, EMA |
| Myocet® | Doxorubicin | Non-PEGylated liposome | Metastatic breast cancer | EMA |
| Vyxeos® | Daunorubicin + Cytarabine | Liposomal co-formulation | Acute myeloid leukemia | FDA, EMA |
| Onivyde® | Irinotecan | Liposomal nanoparticle | Metastatic pancreatic cancer | FDA |
| Marqibo® | Vincristine | Liposomal nanoparticle | Acute lymphoblastic leukemia | FDA |
| Apealea® | Paclitaxel | Polymeric micelle | Ovarian cancer | EMA |

6.2 Ongoing Clinical Trials

Numerous nanomedicine platforms are currently undergoing clinical evaluation to improve therapeutic selectivity and overcome drug resistance. These trials involve targeted nanoparticles, RNA-based nanocarriers, and immunotherapy-integrated nanomedicines.

Lipid nanoparticle-mediated small interfering RNA (siRNA) therapies are gaining traction for oncogene silencing. Additionally, polymeric nanoparticles are being evaluated for the co-delivery of chemotherapeutics and immunomodulatory agents. Gold nanoparticles and magnetic nanoparticles are under investigation for photothermal therapy and imaging-guided treatment, particularly in brain and pancreatic cancers (Blanco et al., 2015; Shi et al., 2020).

Another major clinical trend involves multifunctional nanoplatforms that combine imaging and therapy, enabling real-time monitoring of drug delivery and treatment response. Such theranostic systems are especially promising in tumors with high heterogeneity, where treatment response varies significantly across tumor microenvironments.

6.3 Barriers to Commercialization

Despite promising clinical outcomes, several challenges limit the large-scale commercialization of nanomedicines. Tumor heterogeneity remains a major biological barrier, as nanoparticle distribution varies across tumor types and patient populations. The variability of the EPR effect in human tumors further complicates therapeutic predictability (Danhier, 2016). Manufacturing complexity and high production costs also hinder commercialization. Nanomedicine formulations require precise control over size, surface chemistry, and stability, making scale-up difficult. Additionally, regulatory pathways for nanotherapeutics are often complex due to challenges in standardizing characterization and safety evaluation protocols (Ventola, 2017).

7. Emerging Trends and Future Perspectives

7.1 Personalized and Precision Nanomedicine

Personalized nanomedicine aims to tailor nanoparticle formulations based on patient-specific tumor biology. Advances in genomic



profiling and biomarker identification enable the design of targeted nanocarriers that enhance therapeutic specificity. Personalized nanoplateforms are particularly relevant for breast and lung cancers, where molecular heterogeneity significantly influences treatment outcomes (Shi et al., 2020). Patient-specific drug delivery strategies also allow optimization of dosage regimens and minimize off-target toxicity. Integration of liquid biopsy technologies further enhances patient stratification and treatment monitoring.

7.2 Artificial Intelligence in Nanoparticle Design

Artificial intelligence (AI) and machine learning are revolutionizing nanoparticle engineering by optimizing formulation parameters and predicting biological interactions. AI-driven modeling enables rapid screening of nanoparticle size, shape, surface modifications, and drug loading efficiency, accelerating nanomedicine development. Machine learning algorithms can also predict nanoparticle biodistribution, tumor penetration, and toxicity profiles, reducing reliance on extensive animal studies. AI-based predictive modeling is expected to significantly shorten drug development timelines and improve translational success rates (Paul et al., 2021).

7.3 Combination Therapy Approaches

Combination therapy using nanocarriers allows co-delivery of multiple therapeutic agents, including chemotherapy drugs, immunotherapeutics, and gene-editing tools. Such multifunctional systems enhance synergistic therapeutic effects while reducing drug resistance. Nanoparticles can also facilitate sequential drug release, allowing controlled temporal drug administration. Combination nanotherapies are particularly promising in pancreatic and brain

cancers, where conventional monotherapies demonstrate limited efficacy

7.4 Nanotheranostics and Real-Time Monitoring

Nanotheranostics integrates diagnostic imaging and therapeutic delivery into a single nanoparticle platform. These systems incorporate imaging agents such as fluorescent dyes, magnetic resonance contrast agents, or radionuclides alongside therapeutic drugs.

Real-time monitoring enables clinicians to track nanoparticle accumulation and treatment response, improving clinical decision-making. Gold nanoparticles and quantum dots are widely studied theranostic platforms due to their unique optical and imaging properties (Mura et al., 2013).

7.5 Overcoming Tumor Heterogeneity

Tumor heterogeneity remains a critical obstacle in cancer therapy. Advanced nanoplateforms aim to overcome this limitation through multi-targeting strategies and adaptive drug delivery systems. Stimuli-responsive nanoparticles can release drugs selectively in response to tumor-specific triggers such as pH, hypoxia, or enzymatic activity. Emerging strategies also involve immunomodulating nanoparticles that reshape tumor microenvironments, enhancing immune cell infiltration and improving immunotherapy efficacy. Such approaches hold significant promise in treating aggressive cancers such as glioblastoma and pancreatic adenocarcinoma.

8. Challenges and Knowledge Gaps

Despite substantial progress in cancer nanomedicine, several scientific, translational, and clinical limitations hinder widespread clinical success. Addressing these knowledge gaps is essential for developing tumor-specific and patient-tailored nanotherapeutic strategies.



8.1 Lack of Predictive Preclinical Models

One of the most significant barriers to successful nanomedicine translation is the limited predictive value of conventional preclinical models. Most nanotherapeutics demonstrate promising results in murine tumor models but fail to replicate similar efficacy in human clinical trials. Animal models often exhibit exaggerated enhanced permeability and retention (EPR) effects compared to human tumors, leading to overestimation of nanoparticle accumulation and therapeutic outcomes (Nichols & Bae, 2014). Traditional two-dimensional cell culture systems inadequately replicate tumor heterogeneity, extracellular matrix complexity, and immune microenvironment interactions. Emerging three-dimensional tumor spheroid models and organoids provide improved simulation of tumor architecture and drug penetration patterns. Patient-derived xenograft models further enhance translational accuracy by maintaining tumor heterogeneity and molecular characteristics, although these models remain expensive and technically challenging (Sun et al., 2021). Advanced microfluidic tumor-on-a-chip technologies are increasingly being utilized to simulate vascular perfusion, immune interactions, and drug transport mechanisms. These systems allow real-time monitoring of nanoparticle penetration and therapeutic response, offering improved predictive capabilities for clinical translation.

8.2 Tumor-Specific Nanoparticle Optimization

Tumor heterogeneity significantly influences nanoparticle delivery efficiency. Variations in tumor vascular density, stromal composition, immune cell infiltration, and extracellular matrix architecture require tailored nanoparticle design for each cancer type. For example, pancreatic tumors contain dense stromal barriers that limit nanoparticle penetration, while brain tumors

present blood–brain barrier restrictions that prevent effective drug delivery (Blanco et al., 2015). Nanoparticle properties such as size, surface charge, hydrophobicity, and ligand functionalization must be optimized based on tumor microenvironment characteristics. Smaller nanoparticles demonstrate improved tissue penetration but may undergo rapid systemic clearance. Conversely, larger nanoparticles show prolonged circulation but limited tumor infiltration. Achieving optimal nanoparticle design requires balancing these competing factors (Danhier, 2016). Furthermore, tumor-specific biomarker targeting remains challenging due to heterogeneous receptor expression within and between tumor subtypes. Multi-ligand targeting strategies and stimuli-responsive nanocarriers are emerging approaches to overcome these limitations.

8.3 Patient Variability and Clinical Trial Limitations

Patient-to-patient variability significantly impacts nanomedicine efficacy. Differences in tumor genetics, immune responses, vascular permeability, and metabolic conditions influence nanoparticle biodistribution and therapeutic response. Personalized treatment strategies are therefore essential for maximizing clinical effectiveness. Clinical trials involving nanomedicines often face recruitment challenges due to strict inclusion criteria and tumor subtype variability. Additionally, traditional clinical endpoints may not adequately capture nanomedicine-specific therapeutic mechanisms such as targeted drug accumulation and microenvironment modulation (Hare et al., 2017). Another limitation involves the lack of standardized biomarkers for evaluating nanoparticle delivery efficiency. Imaging-based quantification techniques and circulating tumor



biomarkers are being investigated to improve patient stratification and treatment monitoring.

CONCLUSION

Cancer nanomedicine represents a transformative approach in oncology, offering improved drug delivery, reduced systemic toxicity, and enhanced therapeutic precision. Comparative analysis across breast, lung, brain, and pancreatic cancers highlights significant tumor-specific constraints and therapeutic opportunities. Breast cancer demonstrates considerable responsiveness to receptor-targeted nanotherapeutics, particularly HER2-directed nanoparticle systems. Lung cancer presents unique pulmonary delivery challenges but benefits from inhalable nanoparticle formulations and targeted therapies addressing smoking-related molecular alterations. Brain cancers, especially glioblastoma, remain highly challenging due to blood–brain barrier limitations, requiring advanced nanoparticle transport strategies and theranostic platforms. Pancreatic cancer presents one of the most difficult treatment landscapes due to dense stromal barriers and hypovascular tumor architecture, necessitating stromal-modulating nanoplateforms and combination therapeutic approaches (Shi et al., 2017). The future of cancer nanomedicine lies in individualized therapeutic design that integrates molecular tumor profiling, patient-specific microenvironment characterization, and advanced nanoparticle engineering. Artificial intelligence, multi-functional theranostic systems, and precision nanomedicine strategies are expected to significantly improve treatment outcomes. Continued interdisciplinary collaboration among materials scientists, oncologists, pharmacologists, and regulatory authorities is essential for overcoming translational barriers. Development of predictive preclinical models, standardized regulatory frameworks, and scalable manufacturing

techniques will play crucial roles in accelerating clinical adoption. Ultimately, tumor-specific nanotherapeutic strategies have the potential to revolutionize cancer treatment by enabling personalized, targeted, and adaptive therapeutic interventions. Sustained research and technological innovation will determine the successful integration of nanomedicine into routine clinical oncology practice.

10. Abbreviations

| Abbreviation | Full Form |
|--------------|--|
| AI | Artificial Intelligence |
| BBB | Blood–Brain Barrier |
| CARPA | Complement Activation-Related Pseudoallergy |
| CNS | Central Nervous System |
| CDSO | Central Drugs Standard Control Organization |
| EMA | European Medicines Agency |
| EPR | Enhanced Permeability and Retention |
| FDA | Food and Drug Administration |
| GBM | Glioblastoma Multiforme |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| LNP | Lipid Nanoparticle |
| MRI | Magnetic Resonance Imaging |
| NSCLC | Non-Small Cell Lung Cancer |
| NP | Nanoparticle |
| PEG | Polyethylene Glycol |
| PEGylation | Polyethylene Glycol Surface Modification |
| PLGA | Poly(lactic-co-glycolic acid) |
| RES | Reticuloendothelial System |
| siRNA | Small Interfering Ribonucleic Acid |
| SCLC | Small Cell Lung Cancer |
| SPARC | Secreted Protein Acidic and Rich in Cysteine |
| TME | Tumor Microenvironment |

11. Declarations

Funding



The authors declare that no specific funding was received for this work from any funding agency in the public, commercial, or not-for-profit sectors.

Conflict of Interest

The authors declare that there are no conflicts of interest regarding the publication of this manuscript.

Author Contributions

All authors contributed substantially to the conception, literature review, drafting, revision, and final approval of the manuscript. All authors agree to be accountable for all aspects of the work and ensure the accuracy and integrity of the research.

Ethical Approval

This article is a review study and does not involve any human participants, animal experiments, or clinical data collection. Therefore, ethical approval and informed consent were not required.

REFERENCES

1. Allen, T. M., & Cullis, P. R. (2013). Liposomal drug delivery systems: From concept to clinical applications. *Advanced Drug Delivery Reviews*, 65(1), 36–48. <https://doi.org/10.1016/j.addr.2012.09.037>
2. Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020). The blood–brain barrier and blood–tumor barrier in brain tumors and metastases. *Nature Reviews Cancer*, 20(1), 26–41. <https://doi.org/10.1038/s41568-019-0205-x>
3. Baetke, S. C., Lammers, T., & Kiessling, F. (2015). Applications of nanoparticles for diagnosis and therapy of cancer. *British Journal of Radiology*, 88(1054), 20150207. <https://doi.org/10.1259/bjr.20150207>
4. Barenholz, Y. (2012). Doxil®—The first FDA-approved nano-drug. *Journal of Controlled Release*, 160(2), 117–134. <https://doi.org/10.1016/j.jconrel.2012.03.020>
5. Baskar, R., Lee, K. A., Yeo, R., & Yeoh, K. W. (2012). Cancer and radiation therapy: Current advances and future directions. *International Journal of Medical Sciences*, 9(3), 193–199. <https://doi.org/10.7150/ijms.3635>
6. Bazak, R., Hourri, M., Achy, S. E., Hussein, W., & Refaat, T. (2015). Passive and active targeting in cancer therapy. *Journal of Nanomaterials*, 2015, 1–15. <https://doi.org/10.1155/2015/186428>
7. Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016). Triple-negative breast cancer. *Nature Reviews Clinical Oncology*, 13(11), 674–690.
8. Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gaboritovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., Vonderheide, R. H., Pittet, M. J., Jain, R. K., Zou, W., Howcroft, T. K., Woodhouse, E. C., Weinberg, R. A., & Krummel, M. F. (2018). Understanding the tumor immune microenvironment. *Nature Medicine*, 24(5), 541–550. <https://doi.org/10.1038/s41591-018-0014-x>
9. Blanco, E., Shen, H., & Ferrari, M. (2015). Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nature Biotechnology*, 33(9), 941–951. <https://doi.org/10.1038/nbt.3330>
10. Chabner, B. A., & Roberts, T. G. (2005). Chemotherapy and the war on cancer. *Nature Reviews Cancer*, 5(1), 65–72. <https://doi.org/10.1038/nrc1529>
11. Chauhan, A. S. (2018). Dendrimers for drug delivery. *Molecules*, 23(4), 938. <https://doi.org/10.3390/molecules23040938>



12. Danhier, F. (2016). To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine? *Journal of Controlled Release*, 244, 108–121. <https://doi.org/10.1016/j.jconrel.2016.11.015>
13. Danhier, F., Ansorena, E., Silva, J. M., Coco, R., Le Breton, A., & Pr eat, V. (2012). PLGA-based nanoparticles: An overview of biomedical applications. *Journal of Controlled Release*, 161(2), 505–522. <https://doi.org/10.1016/j.jconrel.2012.01.043>
14. Danhier, F., Feron, O., & Pr eat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers. *Journal of Controlled Release*, 148(2), 135–146. <https://doi.org/10.1016/j.jconrel.2010.08.027>
15. Desai, N. (2018). Nab-technology: A drug delivery platform utilizing endothelial gp60 receptor-based transport and tumor-derived SPARC for targeting. *Drug Delivery and Translational Research*, 8(2), 356–364. <https://doi.org/10.1007/s13346-017-0458-4>
16. Dreaden, E. C., Austin, L. A., Mackey, M. A., & El-Sayed, M. A. (2012). Size matters: Gold nanoparticles in targeted cancer drug delivery. *Therapeutic Delivery*, 3(4), 457–478. <https://doi.org/10.4155/tde.12.21>
17. Erkan, M., Hausmann, S., Michalski, C. W., Fingerle, A. A., Dobritz, M., Kleeff, J., & Friess, H. (2012). The role of stroma in pancreatic cancer. *Pancreatology*, 12(5), 366–371.
18. Fadeel, B., Farcas, L., Hardy, B., V azquez-Campos, S., Hristozov, D., Marcomini, A., Lynch, I., & Valsami-Jones, E. (2018). Advanced tools for the safety assessment of nanomaterials. *Nature Nanotechnology*, 13(7), 537–543. <https://doi.org/10.1038/s41565-018-0185-0>
19. Fadeel, B., & Garcia-Bennett, A. E. (2010). Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles. *Advanced Drug Delivery Reviews*, 62(3), 362–374. <https://doi.org/10.1016/j.addr.2009.11.008>
20. Fang, J., Nakamura, H., & Maeda, H. (2011). The EPR effect: Unique features of tumor blood vessels for drug delivery. *Advanced Drug Delivery Reviews*, 63(3), 136–151. <https://doi.org/10.1016/j.addr.2010.04.009>
21. Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., & Spitznagel, E. L. (2012). Changing epidemiology of small-cell lung cancer. *Journal of Clinical Oncology*, 24(28), 4539–4544.
22. Hare, J. I., Lammers, T., Ashford, M. B., Puri, S., Storm, G., & Barry, S. T. (2017). Challenges and strategies in anti-cancer nanomedicine development. *Advanced Drug Delivery Reviews*, 108, 25–38. <https://doi.org/10.1016/j.addr.2016.04.006>
23. Heldin, C. H., Rubin, K., Pietras, K., &  stman, A. (2004). High interstitial fluid pressure in tumors and its consequences. *Nature Reviews Cancer*, 4(10), 806–813. <https://doi.org/10.1038/nrc1457>
24. Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. *Nature*, 553(7689), 446–454. <https://doi.org/10.1038/nature25183>
25. Holohan, C., Van Schaeybroeck, S., Longley, D. B., & Johnston, P. G. (2013). Cancer drug resistance. *Nature Reviews Cancer*, 13(10), 714–726.
26. Huang, X., El-Sayed, I. H., Qian, W., & El-Sayed, M. A. (2006). Cancer cell imaging and photothermal therapy in the near-infrared region using gold nanorods. *Journal of the*



- American Chemical Society*, 128(6), 2115–2120.
27. Jackson, C. M., Lim, M., & Drake, C. G. (2019). Immunotherapy for brain cancer: Recent progress and future promise. *Clinical Cancer Research*, 25(21), 6359–6365. <https://doi.org/10.1158/1078-0432.CCR-18-2559>
 28. Jain, R. K. (2014). Antiangiogenesis strategies revisited: From starving tumors to alleviating hypoxia. *Cancer Cell*, 26(5), 605–622. <https://doi.org/10.1016/j.ccell.2014.10.006>
 29. Kamaly, N., Yameen, B., Wu, J., & Farokhzad, O. C. (2016). Degradable controlled-release polymers and polymeric nanoparticles. *Chemical Reviews*, 116(4), 2602–2663. <https://doi.org/10.1021/acs.chemrev.5b00346>
 30. Knop, K., Hoogenboom, R., Fischer, D., & Schubert, U. S. (2010). Poly(ethylene glycol) in drug delivery: Pros and cons. *Angewandte Chemie International Edition*, 49(36), 6288–6308. <https://doi.org/10.1002/anie.200902672>
 31. Kulkarni, J. A., Cullis, P. R., & Van Der Meel, R. (2018). Lipid nanoparticles enabling gene therapies. *Nucleic Acid Therapeutics*, 28(3), 146–157. <https://doi.org/10.1089/nat.2018.0721>
 32. Lee, G. Y., Qian, W. P., Wang, L., Wang, Y. A., Staley, C. A., Satpathy, M., Nie, S., Mao, H., & Yang, L. (2021). Theranostic nanoparticles for pancreatic cancer. *ACS Nano*, 15(3), 4680–4696.
 33. Maeda, H., Nakamura, H., & Fang, J. (2013). The EPR effect for macromolecular drug delivery to solid tumors. *Journal of Controlled Release*, 164(2), 138–144. <https://doi.org/10.1016/j.jconrel.2012.01.001>
 34. Mehnert, W., & Mäder, K. (2012). Solid lipid nanoparticles: Production, characterization, and applications. *Advanced Drug Delivery Reviews*, 64, 83–101. <https://doi.org/10.1016/j.addr.2012.09.021>
 35. Mizrahi, J. D., Surana, R., Valle, J. W., & Shroff, R. T. (2020). Pancreatic cancer. *The Lancet*, 395(10242), 2008–2020. [https://doi.org/10.1016/S0140-6736\(20\)30974-0](https://doi.org/10.1016/S0140-6736(20)30974-0)
 36. Monopoli, M. P., Åberg, C., Salvati, A., & Dawson, K. A. (2012). Biomolecular coronas provide the biological identity of nanosized materials. *Nature Nanotechnology*, 7(12), 779–786. <https://doi.org/10.1038/nnano.2012.207>
 37. Mura, S., Nicolas, J., & Couvreur, P. (2013). Stimuli-responsive nanocarriers for drug delivery. *Nature Materials*, 12(11), 991–1003. <https://doi.org/10.1038/nmat3776>
 38. Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000). Role of extracellular matrix assembly in tumor interstitial transport. *Cancer Research*, 60(9), 2497–2503.
 39. Nichols, J. W., & Bae, Y. H. (2014). EPR: Evidence and fallacy. *Journal of Controlled Release*, 190, 451–464. <https://doi.org/10.1016/j.jconrel.2014.03.057>
 40. Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., & Allard, D. (2009). Stromal elements in pancreatic cancer. *Science*, 324(5933), 1457–1461. <https://doi.org/10.1126/science.1171362>
 41. Ostrom, Q. T., Cioffi, G., Gittleman, H., Patil, N., Waite, K., Kruchko, C., & Barnholtz-Sloan, J. S. (2019). CBTRUS statistical report: Primary brain tumors. *Neuro-Oncology*, 21(Suppl 5), v1–v100.
 42. Owens, D. E., & Peppas, N. A. (2006). Opsonization and PEGylation of nanoparticles. *International Journal of Pharmaceutics*, 307(1), 93–102.



- <https://doi.org/10.1016/j.ijpharm.2005.10.010>
43. Patton, J. S., & Byron, P. R. (2007). Inhaling medicines: Delivering drugs to lungs. *Nature Reviews Drug Discovery*, 6(1), 67–74.
 44. Paul, D., Sanap, G., Shenoy, S., Kalyane, D., Kalia, K., & Tekade, R. K. (2021). Artificial intelligence in drug discovery and development. *Drug Discovery Today*, 26(1), 80–93.
<https://doi.org/10.1016/j.drudis.2020.10.010>
 45. Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007). Nanocarriers as an emerging platform for cancer therapy. *Nature Nanotechnology*, 2(12), 751–760.
<https://doi.org/10.1038/nnano.2007.387>
 46. Perou, C. M., Sørlie, T., Eisen, M. B., Van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., & Akslen, L. A. (2000). Molecular portraits of human breast tumours. *Nature*, 406(6797), 747–752.
 47. Quail, D. F., & Joyce, J. A. (2013). Microenvironmental regulation of tumor progression and metastasis. *Nature Medicine*, 19(11), 1423–1437.
<https://doi.org/10.1038/nm.3394>
 48. Saraiva, C., Praça, C., Ferreira, R., Santos, T., Ferreira, L., & Bernardino, L. (2016). Nanoparticle-mediated blood–brain barrier crossing. *Journal of Controlled Release*, 235, 34–47.
 49. Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., & Laramy, J. K. (2018). Blood–brain barrier and brain tumor biology. *Neuro-Oncology*, 20(2), 184–191.
<https://doi.org/10.1093/neuonc/nox160>
 50. Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S. A., & Shaw Wright, G. (2018). Atezolizumab in triple-negative breast cancer. *New England Journal of Medicine*, 379(22), 2108–2121.
 51. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. *Nature Reviews Cancer*, 17(1), 20–37. <https://doi.org/10.1038/nrc.2016.108>
 52. Shi, Y., Van Der Meel, R., Chen, X., & Lammers, T. (2020). The EPR effect and beyond. *Theranostics*, 10(17), 7921–7924.
<https://doi.org/10.7150/thno.49577>
 53. Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2024). Cancer statistics, 2024. *CA: A Cancer Journal for Clinicians*, 74(1), 17–48. <https://doi.org/10.3322/caac.21763>
 54. Stylianopoulos, T., & Jain, R. K. (2013). Combining therapies to improve drug delivery in solid tumors. *Nature Reviews Clinical Oncology*, 10(8), 493–506.
<https://doi.org/10.1038/nrclinonc.2013.105>
 55. Suk, J. S., Xu, Q., Kim, N., Hanes, J., & Ensign, L. M. (2016). PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Advanced Drug Delivery Reviews*, 99, 28–51.
<https://doi.org/10.1016/j.addr.2015.09.012>
 56. Sun, W., Luo, Z., Lee, J., Kim, H. J., Lee, K., Tebon, P., Feng, Y., Dokmeci, M. R., Sengupta, S., & Khademhosseini, A. (2021). Organ-on-a-chip for cancer and immune organ modeling. *Advanced Healthcare Materials*, 10(1), 2001363.
<https://doi.org/10.1002/adhm.202001363>
 57. Szebeni, J. (2014). Complement activation-related pseudoallergy. *Molecular Immunology*, 61(2), 163–173.
<https://doi.org/10.1016/j.molimm.2014.06.038>
 58. Tinkle, S., McNeil, S. E., Mühlebach, S., Bawa, R., Borchard, G., Barenholz, Y., Tamarkin, L., & Desai, N. (2014).



- Nanomedicines: Addressing the scientific and regulatory gap. *Annals of the New York Academy of Sciences*, 1313(1), 35–56. <https://doi.org/10.1111/nyas.12403>
59. Torchilin, V. P. (2014). Multifunctional nanocarriers. *Advanced Drug Delivery Reviews*, 66, 1–2. <https://doi.org/10.1016/j.addr.2013.09.001>
60. Valencia, P. M., Farokhzad, O. C., Karnik, R., & Langer, R. (2012). Microfluidic technologies for accelerating nanoparticle clinical translation. *Nature Nanotechnology*, 7(10), 623–629. <https://doi.org/10.1038/nnano.2012.168>
61. Ventola, C. L. (2017). Progress in nanomedicine: Approved and investigational nanodrugs. *Pharmacy and Therapeutics*, 42(12), 742–755.
62. Waks, A. G., & Winer, E. P. (2019). Breast cancer treatment: A review. *JAMA*, 321(3), 288–300. <https://doi.org/10.1001/jama.2018.19323>
63. Wang, A. Z., Langer, R., & Farokhzad, O. C. (2021). Nanoparticle delivery systems for cancer therapy. *Annual Review of Medicine*, 72, 281–295. <https://doi.org/10.1146/annurev-med-042719-034326>
64. Yao, H., He, G., Yan, S., Chen, C., Song, L., Rosol, T. J., & Deng, X. (2020). Triple-negative breast cancer. *Molecular Cancer*, 19, 1–19.
65. Zhang, P., Zhai, Y., Cai, Y., & Wang, L. (2019). Immunotherapy and nanotechnology in lung cancer. *Cancer Letters*, 461, 1–9.

HOW TO CITE: Yash Srivastav, K. Navaneetha, Amanjot Kaur, Sanjeeta Nayak, Milan Kumar Tarei, Renuka Deshpande, Rishikesh Deshmukh, Swatantr Bahadur Singh, Pratyush Mishra, Tumor-Type–Specific Constraints and Opportunities in Cancer Nanomedicine: A Comparative Review of Therapeutic Nanoplatforms in Breast, Lung, Brain, and Pancreatic Cancers, *Int. J. of Pharm. Sci.*, 2026, Vol 4, Issue 2, 1991-2017. <https://doi.org/10.5281/zenodo.18628035>

